Metropolis Healthcare announced robust financial results for the first quarter of FY27, with revenue from operations rising 17% year-over-year to ₹450.2 crore. EBITDA also saw a significant increase of 27.1% to ₹113.2 crore. The company highlighted strong patient and test volume growth, driven by market penetration and an expanding B2C and B2B segment, alongside growth in Tier III cities.
Metropolis Healthcare Reports Strong Q1FY27 Performance
Metropolis Healthcare Limited has announced its unaudited consolidated financial results for the quarter ended June 30, 2026 (Q1FY27), reporting a strong performance driven by sustained demand and strategic market expansion. The company’s revenue from operations increased by 17% to ₹450.2 crore in Q1FY27, compared to ₹386.1 crore in Q1FY26. This growth was achieved without any price increases, reflecting the continued confidence in the Metropolis brand.
Key Financial Highlights
EBITDA for the quarter surged by 27.1% to ₹113.2 crore, up from ₹89.1 crore in the prior year’s comparable period. The EBITDA margin improved by 210 basis points to 25.2%. Profit After Tax (PAT) also saw a substantial increase of 25.8%, reaching ₹56.9 crore, with PAT margin improving by 90 bps to 12.6%.
Operational Performance Drivers
The company reported a 10% YoY growth in patient volume and an 11% increase in test volume, indicative of deeper market penetration and a shift towards trusted diagnostic chains. B2C revenue grew by 18% YoY, supported by brand pull and digital engagement, while B2B revenue increased by 15% YoY. Specialty diagnostics revenue grew 17% YoY to ₹178 crore, and TruHealth revenue increased 22% YoY to ₹81 crore. Revenue per Patient (RPP) rose by 6% YoY, and Revenue per Test (RPT) improved by 5% YoY.
Market Growth and Strategy
Tier III cities emerged as the fastest-growing markets, with revenue increasing around 25% YoY, significantly outpacing Tier I (11%) and Tier II (14%) cities. This highlights a substantial growth opportunity beyond major metropolitan areas. Metropolis Healthcare continues to invest in scientific innovation, strategic acquisitions, and network expansion to strengthen its leadership in key markets, particularly in North India.
Ms. Ameera Shah, Promoter and Executive Chairperson, stated, “The diagnostics industry is consolidating around trusted, science-led providers as patients increasingly prioritise quality, accuracy and specialised care.” Mr. Surendran Chemmenkotil, Managing Director, added, “Our strong start to the year reflects disciplined execution and the resilience of our business model. Healthy growth in patient and test volumes, together with a 210-basis point expansion in EBITDA margin, demonstrates the quality of our growth and the scalability of our operating model.”
Source: BSE
